Financial Statements 23 Share-Based Payments continued options and restricted Shares Granted during the year Options and restricted shares granted during the year which may vest or become exercisable at various dates between 2017 and 2020 are as follows: Price to be number of paid shares under executive share option and restricted share schemes option Reckitt Benckiser Long-term Incentive Plan 2007 share options 50.57 4,066,654 Reckitt Benckiser Long-term Incentive Plan 2007 restricted shares 2,047,408 Reckitt Benckiser Senior Executives Share Ownership Policy Plan 50,000 Total 6,164,062 Savings-related share option schemes UK Scheme 41.20 279,991 US Scheme 41.88 153,389 Overseas Scheme 41.88 1,086,412 Total 1,519,792 options and restricted Shares outstanding at 31 december 2014 Options and restricted shares which have vested or may vest at various dates between 2015 and 2020 are as follows: Price to be paid number of shares under option executive share option and restricted share schemes From To 2014 2013 Reckitt Benckiser 1999 Share Option Plan Annual Grant 17.60 18.10 106,919 341,750 Reckitt Benckiser Long-term Incentive Plan 2006 Annual Grant options 21.95 22.57 197,892 318,502 Reckitt Benckiser Long-term Incentive Plan 2007 Annual Grant options 26.54 52.25 16,000,642 16,519,694 Reckitt Benckiser Long-term Incentive Plan 2007 Annual Grant restricted shares 6,313,514 6,065,789 Reckitt Benckiser Senior Executives Share Ownership Policy Plan 160,000 180,000 22,778,967 23,425,735 Price to be paid number of shares under option Savings-related share option schemes From To 2014 2013 UK Scheme 21.24 41.20 722,696 605,988 US Scheme 27.99 41.88 565,286 564,477 Overseas Scheme 27.99 41.88 1,897,407 972,385 Total 3,185,389 2,142,850 24 other reserves The merger reserve relates to the 1999 combination of Reckitt & Colman plc and Benckiser N. V. and a Group reconstruction in 2007 treated as a merger under Part 27 of the Companies Act 2006.
The hedging reserve comprises the effective portion of the cumulative net change in fair value of cash flow hedging instruments related to hedge transactions that are extant at year end.
The foreign currency translation reserve contains the accumulated foreign exchange differences from the translation of the financial statements of the Groups foreign operations arising when the Groups entities are consolidated.
The reserve also contains the translation of liabilities that hedge the Groups net exposure in a foreign currency.
25 related Party Transactions Subsequent to the demerger of RB Pharmaceuticals on 23 December 2014, the Group continues to lease a building to, and provide operational services to the newly formed Indivior PLC.
These transitional services between the Group and Indivior PLC are on an arms length basis.
Adrian Hennah, the Reckitt Benckiser Group plc CFO, also sits on the Board of Directors of Indivior PLC.
On 19 March 2013 the Group purchased an additional 25% of Shanghai Manon Trading Company Limited, thereby increasing its share to 75.01%.
The consideration for the transaction amounted to 28m, including transaction costs.
Key management compensation is disclosed in note 5.
The subsidiary undertakings whose results or financial position principally affected the consolidated financial statements at 31 December 2014 are disclosed in note 2 to the Parent Company financial statements.
RB Annual Report and Financial Statements 2014 113
